Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2016-11-16 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 2 pages 133.4KB
Regulatory Filings
2016-11-16 English
Appendix 4C - quarterly 4 pages 162.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including consolidated statements of cash flows for the current quarter and year to date, reconciliation of cash and cash equivalents, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The presence of actual financial data and quarterly period references indicates this is a comprehensive quarterly financial report. The document is 8045 characters long, which is sufficient to contain substantive financial data rather than just an announcement. The document aligns with the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes substantive financial data and analysis. Therefore, the correct classification is IR. Q1 2016
2016-10-30 English
Annual Report to shareholders 60 pages 1.3MB
Regulatory Filings
2016-10-17 English
Notice of Annual General Meeting/Proxy Form 24 pages 162.7KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for Phylogica Limited, detailing the time, place, and agenda of the meeting. It includes resolutions to be voted on, such as adoption of the Remuneration Report, approval of placement capacity, re-election of directors, and issuance of options to related parties. The document also contains proxy voting instructions and explanatory statements related to the meeting agenda. It explicitly states it is a Notice of Meeting and not the actual Annual Report or financial statements. The document is a formal notice sent to shareholders to inform them about the AGM and solicit their votes on various resolutions. Therefore, this document fits the category of AGM Information (AGM-R).
2016-10-17 English
Change of Director's Interest Notice 2 pages 148.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and the value of the transaction. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or other report types. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is 3415 characters, which is consistent with a detailed insider trading notice rather than a full report or announcement. Confidence is high due to the clear match with the definition and content.
2016-10-13 English
Change of Director's Interest Notice 2 pages 149.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and the value of the transaction. The document is a formal notification of a director's personal share transactions, which aligns with the definition of Director's Dealing filings. The document length is 3420 characters, which is consistent with a notice rather than a full report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2016-10-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.